Pfizer Developing New Methods For Detecting Hepatotoxicity Signals
This article was originally published in The Pink Sheet Daily
Current methods for detecting hepatotoxicity have no mathematical basis, Pfizer says. The company plans to evaluate patient data for Rezulin and Trovan, which were the subject of liver toxicity concerns.
You may also be interested in...
Cardiovascular & Renal Drugs Advisory Committee votes against recommending approval for all three indications AstraZeneca is seeking for the anticoagulant. The firm’s proposed risk management plan did not seem adequate to prevent severe liver injury, committee members agree.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.